8-K 1 a13-10598_28k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 

 

FORM 8-K

 

 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): April 24, 2013

 

 

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

(State or Other Jurisdiction of
Incorporation)

 

000-30319

(Commission File Number)

 

94-3265960

(I.R.S. Employer Identification Number)

 

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

(a)                                 The Annual Meeting of Stockholders of the Company was held on April 24, 2013.

 

(b)                                 The nominees listed below were elected directors with the respective votes set forth opposite their names:

 

 

 

Votes for

 

Votes withheld

 

Rick E Winningham

 

87,135,110

 

1,915,103

 

Henrietta Holsman Fore

 

87,138,123

 

1,912,090

 

Robert V. Gunderson, Jr.

 

86,490,856

 

2,559,357

 

Arnold J. Levine. Ph.D.

 

87,185,506

 

1,864,707

 

Burton G. Malkiel, Ph.D.

 

87,197,908

 

1,852,305

 

Peter S. Ringrose, Ph.D.

 

87,195,298

 

1,854,915

 

William H. Waltrip

 

87,169,118

 

1,881,095

 

George M. Whitesides, Ph.D.

 

87,167,921

 

1,882,292

 

William D. Young

 

87,169,348

 

1,880,865

 

 

In a non-binding advisory vote, the stockholders voted to approve the compensation of the Company’s named executive officers disclosed in the Company’s 2013 proxy statement.  The voting results are set forth below:

 

For

 

Against

 

Abstain

 

88,714,953

 

254,724

 

80,536

 

 

The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013.  The voting results are set forth below:

 

For

 

Against

 

Abstain

 

94,498,719

 

324,439

 

36,129

 

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

THERAVANCE, INC.

 

 

 

 

Dated: April 29, 2013

By:

/s/ Michael W. Aguiar

 

 

Michael W. Aguiar

 

 

Chief Financial Officer

 

3